Levetiracetam: profile and news
UCB Receives EMEA Positive Opinion and FDA Approvable Letter for ... Feb 3, 2006
CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra® (levetiracetam) Concentrate (100 mg ... - PharmaLive.com (press release),
UCB Receives EMEA Positive Opinion and FDA Approvable Letter for ... Feb 6, 2006
CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra® (levetiracetam) Concentrate (100 mg ... - Chemie.de (press release),
Keppra as adjunctive treatment in idiopathic generalised epilepsy ... Jan 21, 2006
IGE ) having primary generalised tonic-clonic ( PGTC ) seizures became free from all types of seizures when Keppra ( Levetiracetam ) was administered as an add ... - Xagena.it,
Levetiracetam a Promising Choice of Antiepileptic Drug in the ... Dec 9, 2005
WASHINGTON, DC -- December 9, 2005 -- The antiepileptic drug levetiracetam appears to be particularly promising in elderly patients because of its relatively ... - DG News
New Data on the Use of Keppra(R) (levetiracetam) as Adjunctive ... Dec 6, 2005
...epilepsy (IGE) having primary generalised tonic-clonic (PGTC) seizures became free from all types of seizures when Keppra® (levetiracetam) was administered as ... - Market Wire (press release)
Cost of Newer Epilepsy Drugs Prove Worth in Cutting Overall Health ... Dec 8, 2005
...found when they compared total costs of caring for epileptic patients based on whether the patient was being treated with levetiracetam (Keppra) -- one of the ... - DG News
UCB offers positive update on epilepsy drug Dec 8, 2005
...epilepsy (IGE) having primary generalized tonic-clonic (PGTC) seizures became free from all types of seizures when Keppra (levetiracetam) was administered as ... - Pharmaceutical Business Review
59th Annual AES Meeting Dec 2, 2005
...the Relative Risk of Psychiatric and Behavioral Adverse Events in Pediatric Patients with Refractory Partial Seizures Treated with levetiracetam -- Impact of ... - PR Newswire (press release),
Healthbeat:Epilepsy Drugs for Kids Nov 23, 2005
...has recently approved the use of three medications for children four and older: Topamax® (topiramate), Trileptal® (oxcarbazepine) and Keppra® (levetiracetam ... - WHOI,
Curtain-raiser on living with seizures Nov 25, 2005
Bureau of Epilepsy and by UCB, one of the new international biopharmaceutical manufacturers that produced, among other products, Keppra (levetiracetam). ... - Australian,
UCB Receives FDA Orphan Drug Designation for Brivaracetam for the ... Nov 13, 2005
Brivaracetam, a SV2A ligand that is differentiated from levetiracetam (Keppra®) by its mechanism of action profile[1] has shown a significant antiepileptic ... - Medical News Today (press release),
Clinical trial results for new epilepsy treatment Keppra ... Sep 18, 2005
Paediatric clinical trial results of the new epilepsy treatment Keppra (levetiracetam) were reported in Europe for the first time, at this week's meeting of ... - Medical News Today (press release),
International Approvals: Tarceva, Cipralex, Keppra Sep 26, 2005
...of at least one prior chemotherapy regimen; escitalopram oxalate tablets for the treatment of generalized anxiety disorder; and levetiracetam tablets and oral ... - Medscape (subscription)
European Commission Approves Use of Anti-Epileptic Keppra(R) as ... Sep 21, 2005
BRUSSELS, Belgium, September 22 /PRNewswire/ -- Today UCB announced that the European Commission has approved the use of Keppra(R) (levetiracetam) in the ... - PR Newswire UK (press release),
Cognitive Side Effects of Antiepileptic Drugs in Children Oct 3, 2005
Levetiracetam (Keppra), which has been associated with some reports of irritability and aggression, appears to have a favorable cognitive side-effect profile. ... - Psychiatric Times,
European Commission Approves Use of Anti-Epileptic Keppra(R) as ... Sep 21, 2005
Brussels, Belgium (ots/PRNewswire) - Today UCB announced that the European Commission has approved the use of Keppra(R) (levetiracetam) in the European Union ... - news aktuell (Pressemitteilung),
FDA Safety Labeling Changes: Camptosar, Keppra, Prempro/Premphase Sep 21, 2005
...of irinotecan HCl is recommended in patients who are homozygous for the UDP-glucuronosyltransferase 1A1 (UGT1A1)–*28 allele; use of levetiracetam tablets and ... - Medscape (subscription)
EU Commission Approves Keppra® as Adjunctive Therapy in Children ... Sep 25, 2005
Today UCB announced that the European Commission has approved the use of Keppra® (levetiracetam) in the European Union, as adjunctive therapy in the treatment ... - Medical News Today (press release),
Euronext Brussels) - UCB - European Commission Approves Use of ... Sep 22, 2005
Brussels, BELGIUM - September 22, 2005 - Today UCB announced that the European Commission has approved the use of Keppra® (levetiracetam) in the European Union ... - Euronext,
European Commission Approves Use of UCB's Anti-Epileptic Keppra as ... Sep 22, 2005
September 22, 2005 (Hugin via COMTEX News Network) -- Today UCB announced that the European Commission has approved the use of Keppra(R) (levetiracetam) in the ... - PharmaLive.com (press release),
UCB's Anti-Epileptic Keppra(R) Meets Primary End-Point in ... Sep 15, 2005
This trial compared Keppra® (levetiracetam) to sustained release carbamazepine in newly diagnosed patients, suffering from epilepsy with partial or ... - Yahoo! News (press release)
UCB's Anti-Epileptic Keppra Meets Primary End-Point in Monotherapy ... Sep 15, 2005
This trial compared Keppra(R) (levetiracetam) to sustained release carbamazepine in newly diagnosed patients, suffering from epilepsy with partial or ... - PharmaLive.com (press release),
UCB plans to market new epilepsy drug in Europe Sep 16, 2005
The trial compared Keppra (levetiracetam) to sustained release carbamazepine in newly diagnosed patients suffering from epilepsy with partial or generalized ... - Pharmaceutical Business Review
EMEA Initial marketing authorizations, 30 July 2005 Jul 30, 2005
The Committee adopted opinions for the extension of indications of products that are already authorised on the European Union. * Keppra (levetiracetam), UCB ... - Medical News Today (press release)
EMEA Initial marketing authorizations Jul 31, 2005
Keppra ( levetiracetam ), UCB SA, to extend the indication of adjunctive therapy in the treatment of partial onset seizures with or without secondary ... - I-Newswire.com (press release)
Certolizumab pegol, positive results in two Phase III Crohn'™s ... Jul 26, 2005
UCB'TMs key products in the US are Keppra® (levetiracetam), Zyrtec®' (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex ... - Medical News Today (press release)
Certolizumab Pegol Demonstrates Positive Results in Two Phase III ... Jul 26, 2005
UCB's key products in the US are Keppra® (levetiracetam), Zyrtec®(t) (cetirizine HCl), Tussionex® CIII (hydrocodone polistirex/chlorpheniramine polistirex ... - ArriveNet (press release)
Certolizumab Pegol Demonstrates Positive Results in Two Phase III ... Jul 27, 2005
UCB's key products in the US are Keppra(R) (levetiracetam), Zyrtec(R)(+) (cetirizine HCl), Tussionex(R) CIII (hydrocodone polistirex/chlorpheniramine polistirex ... - PharmaLive.com (press release)
<**results**>
FDA Approves UCB's Keppra(R) for Use in Childhood Epilepsy Jun 27, 2005
...announced today that the US Food and Drug Administration (FDA) has approved the company's anti- epilepsy drug Keppra(R) (levetiracetam) as add-on therapy in ... - dBusinessNews Atlanta (press release)
FDA Approves UCB's Keppra® for Use in Childhood Epilepsy Jun 26, 2005
UCB announced today that the US Food and Drug Administration (FDA) has approved the company's anti-epilepsy drug Keppra® (levetiracetam) as add-on therapy in ... - I-Newswire.com (press release)
FDA Keppra Approval Good News for Children with Epilepsy Jun 24, 2005
LANDOVER, Md., June 24, 2005 /PRNewswire/ -- Today's announcement concerning Food and Drug Administration (FDA) approval of Keppra (levetiracetam) as add- on ... - PharmaLive.com (press release),
FDA Approves UCB's Keppra(R) for Use in Childhood Epilepsy 13 Sep 2002
...announced today that the US Food and Drug Administration (FDA) has approved the company's anti- epilepsy drug Keppra(R) (levetiracetam) as add-on therapy in ... - dBusinessNews Atlanta (press release),
FDA Approves UCB's Keppra® for Use in Childhood Epilepsy Jun 26, 2005
UCB announced today that the US Food and Drug Administration (FDA) has approved the company's anti-epilepsy drug Keppra® (levetiracetam) as add-on therapy in ... - I-Newswire.com (press release)
FDA Keppra Approval Good News for Children with Epilepsy Jun 24, 2005
LANDOVER, Md., June 24, 2005 /PRNewswire/ -- Today's announcement concerning Food and Drug Administration (FDA) approval of Keppra (levetiracetam) as add- on ... - PharmaLive.com (press release),
Research ids neurological disease gene Jun 6, 2005
The binding site for current leading anti-epileptic drug Keppra (levetiracetam) has been isolated in the brain, specifically as a synaptic vesicle protein SV2A ... - Drug Researcher.com,
